Zacks.com on MSN5d
Is the Future Bleak for SAVA Stock Following Another Setback?The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with ...
GlobalData on MSN11d
Africa Specialty Risks secures Sava Re capacityUnder the terms of the agreements, Sava Re will provide up to $10m (€9.25m) in line size for ASR's core classes.
Zacks.com on MSN11d
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage StudyCassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints ...
SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.
Zacks.com on MSN4d
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a TurnaroundThe heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...
Africa Specialty Risks (ASR) has entered binding authority agreements with Slovenia-based reinsurance company Sava Re. Under the terms of the agreements, Sava Re will provide up to $10m in line ...
A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling pressure. The stock has declined 39.5% over the past four weeks. However, given the fact that it is now ...
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback